Evaluating Next-Generation BTK Inhibitors
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal
BTK Overview
First-Generation BTK Inhibitor Ibrutinib
Second-Generation BTK Inhibitor Acalabrutinib
Acalabrutinib and Ibrutinib Dosing
Approved Indications Ibrutinib
Ibrutinib in Relapsed CLL Phase 1 Data
Efficacy of Ibrutinib in Other Disease States
Ibrutinib vs Ofatumumab in Previously Treated CLL
Ibrutinib AEs
Challenges With Ibrutinib Use
Risk Factors for Major Hemorrhage in Patients Treated with Ibrutinib
Management of Atrial Fibrillation
Managing Infections
Mechanisms of Resistance
Acalabrutinib Pharmacodynamics
Acalabrutinib in Relapsed CLL Results
Acalabrutinib in Relapsed CLL AEs
Acalabrutinib in Relapsed/Refractory MCL
Acalabrutinib in Relapsed/Refractory MCL AEs
Management of Acalabrutinib AEs
Acalabrutinib or Ibrutinib?
Guideline Recommendations for Ibrutinib and Acalabrutinib
Second-Generation BTK Inhibitor Pipeline and Other Novel Combinations
Other Novel Combination Trials
Genomic-Driven Ibrutinib Treatment in MCL
Concluding Remarks
Abbreviations
Abbreviations (cont)
Abbreviations (cont)